SPARC achieves enrollment goal in PROSEEK Phase 2 Parkinson’s trial
Sun Pharma Advanced Research Company Ltd. (SPARC) has announced the successful completion of patient enrollment for the PROSEEK study, a significant global Phase 2 clinical ... Read More
Sun Pharmaceutical gets SEZABY FDA approval for neonatal seizures
Sun Pharmaceutical Industries has secured approval for SEZABY (phenobarbital sodium powder for injection) from the US Food and Drug Administration (FDA) for the treatment of ... Read More
SPARC signs licensing deal with Visiox for two ophthalmic drug candidates
Sun Pharma Advanced Research Company (SPARC) has signed a licensing agreement with Visiox Pharma to award exclusive worldwide rights (except for India and Greater China) ... Read More
Sun Pharma Advanced Research signs licensing deal with Biomodifying
Sun Pharma Advanced Research Company (SPARC) has signed an agreement with US-based Biomodifying for the exclusive licensing of the latter’s intellectual property (IP), including all ... Read More
SPARC succeeds in phase 3 trial of PDP-716 in glaucoma patients
Sun Pharma Advanced Research Company (SPARC) has succeeded in a phase 3 clinical trial for PDP-716 ophthalmic suspension, its investigational drug for the treatment of ... Read More